Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases... Show more
A.I.dvisor indicates that over the last year, SMMT has been closely correlated with BCDA. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if SMMT jumps, then BCDA could also see price increases.
| Ticker / NAME | Correlation To SMMT | 1D Price Change % | ||
|---|---|---|---|---|
| SMMT | 100% | -4.81% | ||
| BCDA - SMMT | 70% Closely correlated | -1.96% | ||
| KURA - SMMT | 42% Loosely correlated | -6.39% | ||
| LXEO - SMMT | 41% Loosely correlated | -4.35% | ||
| EDIT - SMMT | 40% Loosely correlated | -3.69% | ||
| CBIO - SMMT | 40% Loosely correlated | -5.13% | ||
More | ||||
a developer of novel medicines
Industry Biotechnology
The 10-day RSI Oscillator for SMMT moved out of overbought territory on September 15, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 instances where the indicator moved out of the overbought zone. In 29 of the 31 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SMMT as a result. In 92 of 103 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for SMMT turned negative on October 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 33 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 69%.
SMMT moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SMMT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +3.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where SMMT advanced for three days, in 246 of 286 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
SMMT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 133 of 151 cases where SMMT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 88%.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. SMMT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 76 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SMMT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.608) is normal, around the industry mean (26.823). P/E Ratio (26.355) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.310) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.